USF2 and B-cell chronic lymphocytic leukemia: Furthermore, combination therapies that pair ROS-inducing agents with inhibitors of autophagy or antioxidant pathways (like p62-Nrf2 and USF2) may enhance therapeutic efficacy and help overcome drug resistance, offering a more effective treatment strategy for CLL.